クローン病市場：KOLの洞察

当レポートでは、TNF阻害剤、Entyvio、Stelara、Skyrizi、Rinvoq、Tremfya、Omvoh、Zeposia、Velsipityなど、クローン病に対する現在および新たな治療法を探ります。これらの治療薬の有効性、安全性、有用性を詳細に分析するとともに、今後の処方動向を形成する可能性のある最近の臨床試験に関する洞察も提供しています。バイオシミラーと皮下注製剤が市場に与える影響を検証し、中等度から重度のクローン病の治療状況がどのように進化しているかを詳細に考察しています。

目次

エグゼクティブサマリー

調査目的

• 上市済み薬剤
  • TNF阻害剤（レミケード、Humira、 Cimzia）
  • エンティビオ（ベドリズマブ、Takeda）
  • ステラーラ（ウステキヌマブ、Johnson & Johnson）
  • Skyrizi（リサンキズマブ;AbbVie）
  • リンヴォック（ウパダシチニブ、AbbVie）
• パイプライン薬剤
  • Tremfya（グセルクマブ、Johnson & Johnson Biotech）
  • オムボ（ミリキズマブ、Lillyー）
  • ゼポシア（オザニモド、Bristol Myers Squibb）
  • ベルシピティ（エトラシモド、Pfizer）

今後の治療動向

• クローン病の将来の治療戦略は、併用療法、IL-23阻害剤、経口療法が有利になる可能性がある
  • FMTはCDに応用できる可能性があるが、その戦略は複雑であり、これまでのところ実証されていない

付録

Explore current and emerging treatments for Crohn's disease, including TNF inhibitors, Entyvio, Stelara, Skyrizi, Rinvoq, Tremfya, Omvoh, Zeposia, and Velsipity. This comprehensive report offers an in-depth analysis of the efficacy, safety, and usability of these treatments, as well as insights into recent clinical trials that could shape future prescribing trends. Examine the impact of biosimilars and subcutaneous formulations on the market, offering a detailed look at how the treatment landscape for moderate-to-severe Crohn's disease is evolving. Gain valuable knowledge on physician and payer preferences, the competitive positioning of pipeline products, and the overall market trends influencing drug therapies for Crohn's disease.

Key brands covered in this report:

• Remicade (infliximab)
• Humira (adalimumab)
• Cimzia (certolizumab pegol)
• Entyvio (vedolizumab)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)
• Rinvoq (upadacitinib)
• Tremfya (guselkumab)
• Omvoh (mirikizumab)
• Zeposia (ozanimod)
• Velsipity (etrasimod)

Key questions answered:

• Which CD therapies are preferred for different patient segments and lines of therapy?
• How do medical professionals perceive the efficacy, tolerability, and ease of administration of these therapies?
• Which recent clinical trials could significantly influence CD prescribing trends?
• How might the use of current and pipeline drugs change in the future?
• What must pipeline products demonstrate to compete with existing CD therapies?
• Which pipeline products are most promising and how might they impact the market?
• How will the CD treatment landscape evolve for different patient segments and therapy lines?

Companies:

AbbVie, Lilly, AstraZeneca, UCB, Pfizer, Merck Sharp & Dohme, Bristol Myers Squibb, Takeda, Johnson & Johnson.

Table of Contents

Executive summary

Research objectives

• Marketed drugs
  • TNF inhibitors (Remicade, Humira, Cimzia)
  • Entyvio (vedolizumab; Takeda)
  • Stelara (ustekinumab; Johnson & Johnson)
  • Skyrizi (risankizumab; AbbVie)
  • Rinvoq (upadacitinib; AbbVie)
• Pipeline drugs
  • Tremfya (guselkumab; Johnson & Johnson Biotech)
  • Omvoh (mirikizumab; Lilly)
  • Zeposia (ozanimod; Bristol Myers Squibb)
  • Velsipity (etrasimod; Pfizer)

Future treatment trends

• Future treatment strategies for Crohn's could favour combinations, IL-23 inhibitors and oral therapies
  • FMT could have some applications in CD, but the strategy is complex and, to date, unproven

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe